Drug-induced liver injury, usually shortened to DILI, is liver damage caused by a medication, a supplement, or a chemical rather than by a virus, alcohol or fat accumulation. It is one of the more common reasons people go looking for a liver-support supplement in the first place, which makes it worth examining what the actual evidence says.
This topic is unusual in the TUDCA literature for two reasons. It contains the clearest example of TUDCA outperforming ursodeoxycholic acid, its parent compound, in a direct comparison. It also contains a 2026 case report describing exactly the scenario a reader of this page might be contemplating, with an outcome worth reading before deciding anything. Nothing here is medical advice.
Key Takeaways
- In rats with estrogen-induced cholestasis, TUDCA prevented the rise in serum bile acids, bilirubin, alkaline phosphatase and GGT. UDCA did not [1].
- Liver ultrastructure in the TUDCA group resembled healthy controls, while both the untreated and the UDCA-treated groups showed significant loss of sinusoidal microvilli [1].
- That study used four rats per group per timepoint and gave the bile acids by injection, not by mouth [1].
- In acetaminophen overdose in mice, N-acetylcysteine plus TUDCA outperformed NAC alone across transaminases, histology, ER stress and inflammatory markers [2]. TUDCA alone was less effective than NAC [2].
- A 2026 case report describes fenbendazole-associated liver injury in a person who was taking TUDCA as an intended hepatoprotective agent [3].
- Acetaminophen overdose is a medical emergency with a time-critical antidote. It is not a supplement situation.
The Estrogen Cholestasis Study
Some drugs cause liver problems by impairing bile flow rather than by killing hepatocytes outright. Synthetic estrogens are a classic example, which is why ethinylestradiol is used as a laboratory model of drug-induced cholestasis, and why this research connects to questions about hormonal contraceptives and liver enzymes.
Rats were treated with ethinylestradiol and then randomly assigned to receive daily injections of placebo, TUDCA or UDCA, for either 4 or 14 days [1].
At 4 days, serum cholic acid and taurocholic acid rose significantly in the estrogen-treated rats, but none of the conventional liver tests differed significantly between the four groups yet [1].
By 14 days the separation was clear. The estrogen group and the estrogen-plus-UDCA group both had significantly raised cholic acid, chenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, bilirubin, alkaline phosphatase and gamma-glutamyltransferase [1]. The estrogen-plus-TUDCA rats had no significant changes in any of those individual bile acids or conventional liver tests [1].
The tissue findings matched. Livers from the TUDCA group looked similar to controls under electron microscopy, while both the estrogen-only and estrogen-plus-UDCA groups showed a significant reduction in sinusoidal microvilli [1].
Why This Result Gets Over-Quoted
This is the study that gets cited whenever someone argues TUDCA is simply a better version of UDCA. On its own terms the result is real and the direction is unambiguous: in this model, the taurine-conjugated form protected and the unconjugated form did not.
The limits are equally real. There were four rats per group per timepoint [1], which is a small sample in which a single outlier moves the result. The bile acids were given by intraperitoneal injection [1], which bypasses the digestive tract and the first-pass metabolism that an oral capsule has to survive, and which changes the concentrations reaching the liver. The model is a specific one, chemical cholestasis from a synthetic estrogen, and does not generalise to every drug that damages a liver. And the year was 1995, without a large replication programme following it.
The correct reading is that this is a genuine and interesting signal that TUDCA and UDCA are not interchangeable, not that TUDCA is proven superior in humans.
Acetaminophen: The Combination Finding
Acetaminophen overdose is the most common cause of acute liver failure in several countries, and it has an established antidote in N-acetylcysteine. Mice were given acetaminophen at 300 mg/kg, then two hours later received TUDCA, NAC, or both, and were assessed 24 hours after that [2].
The overdose produced the expected picture: raised transaminases, hepatocyte death, activation of the unfolded protein response, oxidative stress, NLRP3 inflammasome activation and inflammatory cytokine expression [2].
Both treatments helped, but not equally. NAC, the standard of care, produced the larger effect; TUDCA helped to a lesser extent [2]. The notable result was the combination, which improved transaminases, liver histopathology, the ER stress marker CHOP, oxidative stress, caspase 1, NLRP3, IL-1β and inflammatory cytokine expression to a greater extent than NAC alone [2].
That is a legitimate mechanistic argument: NAC replenishes glutathione and handles the toxic metabolite, while TUDCA addresses a different part of the injury, the ER stress and apoptosis arm. Two mechanisms, additive effect.
The practical caveat is severe. This is mouse work, the treatments were given two hours after the overdose under controlled conditions [2], and human acetaminophen poisoning is an emergency where the antidote’s effectiveness depends heavily on how quickly it is started. Nobody experiencing or suspecting an overdose should be reaching for a supplement. That is an emergency-department situation, and delay is the thing that kills people.
The 2026 Case Report Worth Sitting With
Everything above is animal research. There is one recent human data point, and it points in an uncomfortable direction.
A 2026 case report in the ACG Case Reports Journal describes drug-induced liver injury associated with fenbendazole, an anti-parasitic drug that has circulated online as an unproven cancer treatment, in a patient who was concurrently taking TUDCA as an intended hepatoprotective agent [3]. The authors note it is, to their knowledge, the first published report of this exposure combination, and frame it within a growing literature on liver injury from non-prescription drugs taken on the basis of internet and social media influence [3].
A single case report proves very little in isolation. It does not show that TUDCA caused or worsened the injury, and it cannot rule out that the injury would have been worse without it. What it does illustrate is the failure mode: taking TUDCA as liver protection did not prevent significant drug-induced liver injury from a hepatotoxic drug. The authors’ own emphasis is on the importance of patient-centred counselling [3].
The risk this describes is not really a pharmacological one. It is behavioural. A protective supplement can function as permission to take a risk that would otherwise have been declined, and the protection is not established while the risk is.
What This Evidence Supports
Taken together: TUDCA has a mechanistically coherent case in drug-induced liver injury, it outperformed UDCA in one small rat model of estrogen cholestasis [1], and it added to standard antidote therapy in a mouse model of acetaminophen overdose [2]. That is a reasonable basis for continued research and for clinical trials.
It is not a basis for taking a hepatotoxic drug more comfortably, for delaying medical care during a suspected overdose, or for self-treating unexplained liver enzyme elevations. Raised liver enzymes have a differential diagnosis that includes conditions with specific treatments and meaningfully different prognoses, and the first useful step is finding out which one is present.
Frequently Asked Questions
Is TUDCA better than UDCA for drug-induced liver problems?
In one rat study of estrogen-induced cholestasis, TUDCA prevented the biochemical and structural changes and UDCA did not [1]. That study used four rats per group and injected the compounds rather than giving them orally [1]. It shows the two are not interchangeable; it does not establish superiority in people.
Does TUDCA protect against acetaminophen damage?
In mice, TUDCA helped less than N-acetylcysteine on its own, and the combination of the two outperformed NAC alone [2]. Human acetaminophen overdose is a medical emergency with a time-critical antidote, and no supplement substitutes for emergency care.
Can I take TUDCA to protect my liver while taking a hepatotoxic drug?
There is no human trial supporting that use. The one published human report of this exact scenario describes significant drug-induced liver injury occurring while TUDCA was being taken as protection [3]. Anyone on a medication with liver risk should be following the monitoring plan their prescriber set, which usually means periodic blood tests.
What about liver enzymes raised by birth control?
The estrogen cholestasis model is the laboratory analogue of that situation, and it is rat work with injected bile acids [1]. Raised liver enzymes on any hormonal medication are worth investigating with the prescriber rather than managing with a supplement, because the cause determines whether the medication should continue.
References
- Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Journal of Gastroenterology and Hepatology (1995).
- Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver International (2017).
- Fenbendazole-Associated Drug-Induced Liver Injury with Concomitant Use of Tauroursodeoxycholic Acid. ACG Case Reports Journal (2026).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
